PositiveID Corporation
("PositiveID" or "Company") PSID, a developer of biological detection
and diagnostics solutions, announced today that Chairman and CEO William J.
Caragol released a letter to stockholders.
Dear Fellow Stockholders:
I am extremely proud of what the PositiveID team accomplished during 2014,
including the Company's first revenue generation since launching our business
plan in 2011. I am eager to kick off 2015 so that we can continue to build
upon our many successes achieved over the past year. I would also like to
thank you, our stockholders, for your support and faith in our team and our
products. For those of you who have been with us over the years, I believe
there continue to be many significant opportunities ahead and ensure to you
that we are ready to capitalize on these opportunities to deliver value for
our stockholders.
As you may recall, we achieved several key milestones and forged noteworthy
relationships in 2014 with world-class partners, both government and
commercial. In November, we also entered into a $4 million financing that, we
believe, will help us to bring our Firefly Dx technology to field testing and
commercialization.
I have summarized below the status of our two main products and highlighted
what we expect to achieve in 2015.
M-BAND
In 2014, we entered into an agreement with a large government contractor to
support a contract for the U.S. Department of Defense ("DoD") to support the
Joint United States Forces Korea Portal and Integrated Threat Recognition
("JUPITR") Program. We also shipped M-BAND systems to the Korean peninsula and
Aberdeen Proving Ground in Maryland for continued testing as part of the
JUPITR program. The contract had a total value to PositiveID of $1 million.
On December 16, 2014, the U.S. Department of Homeland Security ("DHS")
released a request for information ("RFI") related to automated detection
systems for the BioWatch system. We believe that the beginning of the
procurement process and our teaming and license agreements currently in place,
position us well for the next steps in the rollout of M-BAND in 2015. We
expect to continue operational testing and evaluation of M-BAND in 2015,
positioning us well for potential opportunities in both DoD and DHS markets.
In April of last year, we announced a teaming partner was awarded a prime
contract by the U.S. Defense Threat Reduction Agency ("DTRA") to conduct
research and development to combat weapons of mass destruction. The
multiple-award indefinite delivery/indefinite quantity ("ID/IQ") contract has
a total value of approximately $4 billion for all awardees, if all options are
exercised. Both our Firefly Dx system and M-BAND airborne bio-threat detector
are part of the teaming agreement.
Firefly Dx
In 2014 we accelerated the prototype development of Firefly Dx, our real-time,
hand held, polymerase chain reaction (PCR) pathogen detection system, and
engaged specialized engineering firm Infinite Vision. We also announced two
U.S. government agreements related to Firefly Dx, including a SenseNet Program
contract from the U.S. Department of the Interior on behalf of DHS, and a U.S.
Special Operations Command ("USSOCOM") Cooperative Research and Development
Agreement with Special Operations Research, Development, & Acquisition Center,
Science & Technology Directorate, to further develop Firefly Dx for use across
the USSOCOM mission space.
In May 2014, we announced we signed a Space Act Agreement with NASA's Ames
Research Center. Under this Space Act Agreement, NASA will assess our Firefly
Dx technology for potential ground and space applications, while we assess the
Firefly Dx technology to improve the development of its hardware for extreme
environments, such as DoD field applications.
We are continuing to pursue several U.S. government agency contracts for the
continued development of Firefly Dx. We are seeking these development contract
opportunities to de-risk and co-fund the final stages of Firefly Dx
development, in a model similar to the one used to complete M-BAND. We
anticipate completing the second phase prototype of Firefly Dx in the first
half of 2015, which will enable us to demonstrate the technology and run data
for potential partners, an important step in the development of the final
prototype.
The global PCR market is vast, and is projected to reach approximately $27.4
billion by 2015, according Research and Markets' "Polymerase Chain Reaction
(PCR) - Products/Tools - A Global Market Watch, 2009-2015." We are aiming for
this large market with Firefly Dx and believe we can begin the ramp of
commercial sales of the product in 2016 and 2017.
In closing, I hope you remain as excited about the prospects for PositiveID as
we are. I am proud of what we accomplished in 2014, including our contracts
and agreements, and the relationships we have fostered to enhance our
positioning and underscore the validity and promise of our technology,
products and our team. We believe that we are well positioned to outperform
last year in 2015, with backlog revenue double that which has been recognized
to date, and a significant revenue pipeline for 2015 and 2016.
We are dedicated to delivering continued execution for our stockholders and,
importantly, are prepared to benefit from the opportunities ahead. We plan to
hold a conference call later this month to more fully review these results and
our plans for 2015 and beyond. Please watch for coming details. I thank you
for staying with us on this journey.
Happy New Year!
William J. Caragol
Chairman and Chief Executive Officer
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in